AO-176

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity) . AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma[1][2][3][4].

2691109-74-5

12352203

CD47

Immunology/Inflammation

Cancer-programmed cell death

Cancer

[1]Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19 (3) :835-846.|[2]Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206 (4) :712-721. |[3]William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1) : 3–4|[4]John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1) : 1844.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991561/

Inhibitory Antibodies

No Development Reported